Javascript must be enabled to continue!
Cancer statistics, 2018
View through CrossRef
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005‐2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006‐2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non‐Hispanic blacks (NHBs) than non‐Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13‐1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29‐1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06‐1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16‐3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56‐2.02), Kansas (DRR, 1.51; 95% CI, 1.25‐1.81), Louisiana (DRR, 1.49; 95% CI, 1.38‐1.60), Illinois (DRR, 1.48; 95% CI, 1.39‐1.57), and California (DRR, 1.45; 95% CI, 1.38‐1.54). Larger racial inequalities in young and middle‐aged adults probably partly reflect less access to high‐quality health care.
CA Cancer J Clin 2018;68:7‐30
. ©
2018 American Cancer Society
.
Title: Cancer statistics, 2018
Description:
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival.
Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.
Mortality data, available through 2015, were collected by the National Center for Health Statistics.
In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States.
Over the past decade of data, the cancer incidence rate (2005‐2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006‐2015) declined by about 1.
5% annually in both men and women.
The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Of the 10 leading causes of death, only cancer declined from 2014 to 2015.
In 2015, the cancer death rate was 14% higher in non‐Hispanic blacks (NHBs) than non‐Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.
14; 95% confidence interval [95% CI], 1.
13‐1.
15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.
31; 95% CI, 1.
29‐1.
32) compared with those aged ≥65 years (DRR, 1.
07; 95% CI, 1.
06‐1.
09) and varied substantially by state.
For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.
89; 95% CI, 2.
16‐3.
91) and about 50% higher in Wisconsin (DRR, 1.
78; 95% CI, 1.
56‐2.
02), Kansas (DRR, 1.
51; 95% CI, 1.
25‐1.
81), Louisiana (DRR, 1.
49; 95% CI, 1.
38‐1.
60), Illinois (DRR, 1.
48; 95% CI, 1.
39‐1.
57), and California (DRR, 1.
45; 95% CI, 1.
38‐1.
54).
Larger racial inequalities in young and middle‐aged adults probably partly reflect less access to high‐quality health care.
CA Cancer J Clin 2018;68:7‐30
.
©
2018 American Cancer Society
.
Related Results
Predictors of Statistics Anxiety Among Graduate Students in Saudi Arabia
Predictors of Statistics Anxiety Among Graduate Students in Saudi Arabia
Problem The problem addressed in this study is the anxiety experienced by graduate students toward statistics courses, which often causes students to delay taking statistics cours...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Purpose:
To make a diagnosis of cancer with BDORT (resonance test), we can choose two methods. One is to use a chemical agent like Integrin α5β1 or Oncogene C-f...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Abstract ED02-04: Intersection of cancer, aging, and survivorship
Abstract ED02-04: Intersection of cancer, aging, and survivorship
Abstract
Cancer is a disease associated with aging, with approximately 60% of cancer diagnoses occurring in patients age 65 and older. Of 10.8 million cancer survivo...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
A world without statistics?
A world without statistics?
s a practicing statistician, we frequently are asked questions like: What is the role of statistics in our daily life? Why do we need statistics? What would the world be without st...

